Citi raised the firm’s price target on Ascendis Pharma (ASND) to $290 from $243 and keeps a Buy rating on the shares post the Q2 report. The firm says Yorvipath posted strong sales and is on its way to becoming a blockbuster.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $295 from $289 at Wells Fargo
- Ascendis Pharma’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Yorvipath Performance and Strategic Pipeline Developments
- Ascendis Pharma Reports Strong Q2 2025 Growth
- Ascendis Pharma: Strong Product Performance and Growth Potential Drive Buy Rating
- Ascendis Pharma Reports Increased Revenue but Sustained Losses in H1 2025